Please find the ASX announcement here. Bioxyne divests its COPD related HI-164OV research program for up to $1.56 million.
..Two largest shareholders to vote against remuneration report 20 November 2013: Leading Australian life sciences investment group BioScience Managers today confirmed it will vote against the remuneration report of spray-on skin company Avita Medical Limited (ASX:AVH) at the company’s AGM on Friday 22 November. With the company’s largest shareholder Australian Ethical also set to vote against […]
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate Link here. ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals Inc. (“Biota”) (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate (“LANI”), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a […]
Financial report 2013 link here.
Link here. Date of Meeting: 22 November 2013 Time of Meeting: 2pm WST Place of meeting: Function Room, QV1, 250 St Georges Terrace, Perth, WA 6000
Link to the investor presentation here.
Pharmaxis announcement link here. Pharmaceutical company Pharmaxis today announced the retirement of two non‐executive directors, Dr John Villiger and Mr Richard van den Broek. Dr Villiger joined the Board in November 2006. His career in the global pharmaceutical industry as a founder of The Medicines Company Inc. brought considerable clinical, regulatory and entrepreneurial experience to the […]
Auckland, New Zealand, September 6th 2013 – Nexus6 Ltd, a digital health company dedicated to improving respiratory care, today announced three appointments to its senior management team following the Company’s successful US$3.6m financing earlier in 2013. Nexus6 is a global leader in the development and manufacturing of intelligent monitoring solutions that improve the management of COPD and […]
Avita Medical ASX announcement link here.